期刊： BLOOD CANCER DISCOVERY, 2022; 3 (6)
Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging d......
期刊： BLOOD CANCER DISCOVERY, 2021; 2 (4)
The PML/RAR alpha fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RAR alpha-tar......
期刊： BLOOD CANCER DISCOVERY, 2021; 2 (5)
As a general rule, successful antineoplastic treatments induce an antitumor immune response, even if they were initially designed to target cancer cel......
